抗癌治疗的肾毒性效应:第34届急性疾病质量倡议工作组共识报告
过去数十年,传统化疗、靶向治疗、免疫治疗及细胞治疗(如造血干细胞移植和嵌合抗原受体T细胞治疗)快速发展,但其肾毒性效应在预防、诊断和管理上仍存大量未解问题。此外,急性肾损伤或慢性肾脏病患者及接受肾脏替代治疗患者的肾功能评估和药物剂量缺乏共识与精确指导,限制了救命治疗的可及性并危及预后。本共识声明基于第34届急性疾病质量倡议会议,由肾脏病学、血液病学、肿瘤学、肾脏病理学、重症医学、儿科和药理学国际专家组制定,提供成人抗癌治疗肾毒性的预防、诊断和管理指导,并定义研究议程。
要点
- 共识由第34届急性疾病质量倡议会议国际专家组制定,涵盖肾脏病学、血液病学、肿瘤学、肾脏病理学、重症医学、儿科和药理学。
- 抗癌治疗肾毒性的预防、诊断和管理仍存在大量未解问题,共识提供成人患者相关指导。
- 急性肾损伤或慢性肾脏病患者及接受肾脏替代治疗患者的肾功能评估和药物剂量缺乏共识与精确指导,限制救命治疗可及性并危及预后。
- 共识定义研究议程,聚焦预防和减轻抗癌治疗毒性、最大化肾毒性早期检测、实现肾病患者最佳药物剂量。
适用人群与场景
- 成人接受抗癌治疗(传统化疗、靶向治疗、免疫治疗、细胞治疗如造血干细胞移植和嵌合抗原受体T细胞治疗)的患者。
研究设计与关键结果
- 第34届急性疾病质量倡议会议召集肾脏病学、血液病学、肿瘤学、肾脏病理学、重症医学、儿科和药理学国际专家组,制定成人抗癌治疗肾毒性预防、诊断和管理指导。
- 共识指出抗癌治疗肾毒性的预防、诊断和管理仍存在大量未解问题。
- 共识指出急性肾损伤或慢性肾脏病患者及接受肾脏替代治疗患者的肾功能评估和药物剂量缺乏共识与精确指导,限制救命治疗可及性并危及预后。
- 共识定义研究议程,聚焦预防和减轻抗癌治疗毒性、最大化肾毒性早期检测、实现肾病患者最佳药物剂量。
证据类型、等级与局限
- 证据类型:共识报告(第34届急性疾病质量倡议工作组)。
- 局限:原文未报告局限性
对床旁实践的改变
- 原文未据此给出推荐
指南或共识出处
- 第34届急性疾病质量倡议工作组共识报告(Nat Rev Nephrol)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
In the past few decades, advances in understanding of cancer biology have led to the development of highly effective conventional chemotherapies, targeted therapies that act on specific pathways that are critical to cancer growth, immune-based therapies, and cellular therapies such as haematopoietic cell transplantation and chimeric antigen receptor T cell therapy. However, the nephrotoxic effects of these therapies continue to pose substantial challenges, with many unanswered questions regarding the prevention, diagnosis and management of this nephrotoxicity. Further, a lack of consensus and precise guidance on kidney function estimation and drug dosing for patients with acute kidney disease or chronic kidney disease and for patients receiving kidney replacement therapy limits access to life-saving therapies and jeopardizes outcomes. In this Consensus Statement, we present guidance on the prevention, diagnosis and management of anticancer therapy nephrotoxicity for adult patients that was developed at the 34th Acute Disease Quality Initiative meeting, which convened an international panel of experts in nephrology, haematology, oncology, nephropathology, critical care, paediatric care and pharmacology. We also define a research agenda focused on preventing and mitigating anticancer therapy toxicity, maximizing early detection of nephrotoxicity and enabling optimal drug dosing in patients with kidney disease, with the goal of advancing cancer care and fulfilling the potential of these ground-breaking treatments.
参考来源
- Renaghan AD, Ostermann M, Ronco C, et al. The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroup. Nat Rev Nephrol. 2025. PMID: 41361704. doi:10.1038/s41581-025-01031-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。